Publication:
Roles of pyridine and pyrimidine derivatives as privileged scaffolds in anticancer agents

Simple item page
dc.contributor.authorPrachayasittikul S.
dc.contributor.authorPingaew R.
dc.contributor.authorWorachartcheewan A.
dc.contributor.authorSinthupoom N.
dc.contributor.authorPrachayasittikul V.
dc.contributor.authorRuchirawat S.
dc.contributor.authorPrachayasittikul V.
dc.date.accessioned2021-04-05T03:23:12Z
dc.date.available2021-04-05T03:23:12Z
dc.date.issued2017
dc.date.issuedBE2560
dc.description.abstractBackground: Cancer has been considered to be a global health concern due to the impact of disease on the quality of life. The continual increase of cancer cases as well as the resistance of cancer cells to the existing drugs have driven the search for novel anticancer drugs with better potency and selectivity, improved pharmacokinetic profiles, and minimum toxicities. Pyridine and pyrimidine are presented in natural products and genetic materials. These pyridine/pyrimidine core structures have been noted for their roles in many biological processes as well as in cancer pathogenesis, which make such compounds become attractive scaffolds for discovery of novel drugs. Results & Conclusion: In the recent years, pyridine- and pyrimidine-based anticancer drugs have been developed based on structural modification of these core structures (i.e., substitution with moieties and rings, conjugation with other compounds, and coordination with metal ions). Detailed discussion is provided in this review to highlight the potential of these small molecules as privileged scaffolds with attractive properties and biological activities for the search of novel anticancer agents. © 2017 Bentham Science Publishers.
dc.format.mimetypeapplication/pdf
dc.identifier.citationMini-Reviews in Medicinal Chemistry. Vol 17, No.10 (2017), p.869-901
dc.identifier.doi10.2174/1389557516666160923125801
dc.identifier.issn13895575
dc.identifier.other2-s2.0-85025119431
dc.identifier.urihttps://hdl.handle.net/20.500.14740/4836
dc.rights.holderScopus
dc.subject.other1,2,3 triazole derivative
dc.subject.other1,4 naphthoquinone
dc.subject.other2,4 diphenoxy 6 aryl pyridine
dc.subject.other2,4 diphenoxy pyridine
dc.subject.other2,4 diphenoxyl 6 heteroaryl pyridine
dc.subject.other2,4 diphenyl 6 aryl pyridine
dc.subject.other2,4 diphenyl 6 heteroaryl pyridine
dc.subject.other2,4,6 triheteroaryl pyridine
dc.subject.other2,4,6 triphenyl pyridine
dc.subject.other2,6 diaminopyridine
dc.subject.other2,6 diphenyl 4 heteroaryl pyridine
dc.subject.other3 aminopicolinaldehyde thiosemicarbazone
dc.subject.other3 aminopyridine thiosemicarbazone
dc.subject.other3,5 disubstituted pyridine
dc.subject.other4 chromanone derivative
dc.subject.otherAnthranilic acid
dc.subject.otherAntineoplastic agent
dc.subject.otherCoumarin
dc.subject.otherDoxorubicin
dc.subject.otherIsoflavone
dc.subject.otherNicotinamide
dc.subject.otherPicoline derivative
dc.subject.otherPyridine derivative
dc.subject.otherPyrimidine derivative
dc.subject.otherQuinoline
dc.subject.otherRibonucleotide reductase
dc.subject.otherTetrahydroisoquinoline
dc.subject.otherThiadiazole derivative
dc.subject.otherThiosemicarbazone derivative
dc.subject.otherUnclassified drug
dc.subject.otherUnindexed drug
dc.subject.otherAntineoplastic agent
dc.subject.otherPyridine derivative
dc.subject.otherPyrimidine derivative
dc.subject.otherA-549 cell line
dc.subject.otherAntineoplastic activity
dc.subject.otherAntiproliferative activity
dc.subject.otherApoptosis
dc.subject.otherBreast cancer
dc.subject.otherCancer cell
dc.subject.otherCancer therapy
dc.subject.otherCell growth
dc.subject.otherCell survival
dc.subject.otherChronic myeloid leukemia
dc.subject.otherColorectal cancer
dc.subject.otherDNA repair
dc.subject.otherErectile dysfunction
dc.subject.otherHep-G2 cell line
dc.subject.otherIC50
dc.subject.otherKidney carcinoma
dc.subject.otherNeoplasm
dc.subject.otherNon small cell lung cancer
dc.subject.otherNonhuman
dc.subject.otherProstate cancer
dc.subject.otherQuality of life
dc.subject.otherReview
dc.subject.otherTumor suppressor gene
dc.subject.otherChemistry
dc.subject.otherDNA damage
dc.subject.otherDrug effects
dc.subject.otherHuman
dc.subject.otherStructure activity relation
dc.subject.otherSynthesis
dc.subject.otherAntineoplastic Agents
dc.subject.otherCell Survival
dc.subject.otherDNA Damage
dc.subject.otherHumans
dc.subject.otherPyridines
dc.subject.otherPyrimidines
dc.subject.otherStructure-Activity Relationship
dc.titleRoles of pyridine and pyrimidine derivatives as privileged scaffolds in anticancer agents
dc.typeReview
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85025119431&doi=10.2174%2f1389557516666160923125801&partnerID=40&md5=8579905d52458c712981439463f18b4a

Files

Collections

Scopus: Year 1983-2021